Veterinary Medicine Information website

Febrivac 3-Plus

Not authorised
  • Mink enteritis virus, Inactivated
  • Pseudomonas aeruginosa, serotype 5, strain EP3, Inactivated
  • Clostridium botulinum, type C, strain Stockholm, toxoid
  • Pseudomonas aeruginosa, serotype 6, strain EP2, Inactivated
  • Pseudomonas aeruginosa, serotype 7/8, strain EP1, Inactivated
Download as PDF

Product identification

Medicine name:
Febrivac 3-Plus
Active substance:
  • Mink enteritis virus, Inactivated
  • Pseudomonas aeruginosa, serotype 5, strain EP3, Inactivated
  • Clostridium botulinum, type C, strain Stockholm, toxoid
  • Pseudomonas aeruginosa, serotype 6, strain EP2, Inactivated
  • Pseudomonas aeruginosa, serotype 7/8, strain EP1, Inactivated
Target species:
  • Mink
Route of administration:
  • Subcutaneous use

Product details

Active substance and strength:
  • Mink enteritis virus, Inactivated
    10000.00
    50% tissue culture infectious dose
    /
    1.00
    millilitre(s)
  • Pseudomonas aeruginosa, serotype 5, strain EP3, Inactivated
    100000000.00
    cells
    /
    1.00
    millilitre(s)
  • Clostridium botulinum, type C, strain Stockholm, toxoid
    0.50
    relative unit(s)
    /
    1.00
    millilitre(s)
  • Pseudomonas aeruginosa, serotype 6, strain EP2, Inactivated
    100000000.00
    cells
    /
    1.00
    millilitre(s)
  • Pseudomonas aeruginosa, serotype 7/8, strain EP1, Inactivated
    100000000.00
    cells
    /
    1.00
    millilitre(s)
Pharmaceutical form:
  • Suspension for injection
Anatomical therapeutic chemical veterinary (ATCvet) codes:
  • QI20CL01
Legal status of supply:
  • Veterinary medicinal product subject to veterinary prescription
Authorisation status:
  • Surrendered
Authorised in:
  • Germany
Package description:

Additional information

Entitlement type:
  • Marketing Authorisation
Legal basis of product authorisation:
  • Immunological veterinary medicinal product application (Article 13d of Directive No 2001/82/EC)
Marketing authorisation holder:
  • IDT Biologika GmbH
Marketing authorisation date:
Manufacturing sites for batch release:
  • IDT Biologika GmbH
Responsible authority:
  • Paul-Ehrlich-Institut
Authorisation number:
  • 137a/92
Date of authorisation status change:

Documents

Summary of Product Characteristics

This document does not exist in this language (English). You can find it in another language below.
German (PDF)
Published on: 4/09/2025
Download

Package Leaflet

This document does not exist in this language (English). You can find it in another language below.
German (PDF)
Published on: 4/09/2025
Download